PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBioPharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis (ISA), taking place in Rochester, Minnesota on May 26 - 30, 2024.

BridgeBio will also host an investor call on May 29, 2024, at 5:30 pm ET to discuss the recent analyses and positive data from the ATTRibute-CM Phase 3 trial and emerging real-world evidence in ATTR-CM. The investor call will include presentations from Mathew Maurer, M.D. of  Columbia University Irving Medical Center and Ahmad Masri, M.D., M.S. of Oregon Health & Science University.

To access the oral presentations and moderated poster presentations following the Company’s participation at the 2024 ISA, please visit investor.bridgebio.com/presentations.